Shanghai, March 21, 2024 /PRNewswire/ — Mabwell (688062.SH), an innovation-driven biopharmaceutical company with an entire industry chain, says, “The Mtoxin™ payload applied to the IDDC™ ADC platform significantly increases the therapeutic index and is effective in treating a variety of tumors. He gave a poster presentation titled “Overcoming multidrug resistance in the field of medicine.” March 12-15, 2024 at 2pmth World ADC London. Several ADC drug developments have been demonstrated leveraging the capabilities of IDDC™, a next-generation ADC technology platform.

Poster presentation summary

Advances in coupling technologies, new release structures, and multi-mechanism payloads have driven the development of the ADC field. However, further improvements in drug delivery and overcoming drug resistance are urgent challenges for the next generation of ADC drugs. Mabwell has independently developed IDDC™ technology and a new payload, Mtoxin™. Research results show that:

1. DARfinity™ produces site-specific binding drugs based on DAR 4 (DAR 4 ≥ 95%).

2. IDconnect™ improves plasma stability and payload transfer efficiency of ADC drugs (40% increase over control group).

3. LysOnly™ technology enhances the tumor-specific release ability of ADC drugs and reduces off-target effects.

4. Mtoxin™ has excellent tumor penetration, bystander killing efficacy, and anti-multidrug resistance.

5. ADC medicines developed based on IDDC™ and Mtoxin™ have excellent pharmacodynamic and safety properties, especially in multidrug-resistant models of DXd resistance.


IDDC™ is a clinically validated site-specific binding technology with superior uniformity, efficacy, and safety benefits. Additionally, the novel payload Mtoxin™ (MF6) possesses excellent pharmacodynamics, bystander killing efficacy, and anti-multidrug resistance.

Novel ADC drugs developed based on the IDDC™ platform

The IDDC™ platform has been validated with multiple drugs under investigation.

9MW2821 – Novel Nectin 4-targeted ADC:
9MW2821, indicated for urothelial cancer, is the first Nectin-4 ADC developed by a Chinese company to enter Phase III clinical trials, and the second in the world in terms of progress. 9MW2821 is also the world's first therapy targeting the same target and has published clinical efficacy data for the cervical cancer and esophageal cancer indications. has been granted Fast Track designation by US Food and Drug Administration (FDA) Used to treat advanced, recurrent, or metastatic esophageal squamous cell carcinoma.

7MW3711 – New B7-H3 target ADC:
7MW3711 is in clinical trials in advanced solid tumors. Chinahas received FDA approval for clinical trials in patients with advanced malignant solid tumors.

9MW2921 – New Trop-2 Target ADC:
9MW2921 is undergoing clinical trials in advanced solid tumors. China.

About Mabwell

Mabwell (688062.SH) is an innovation-driven biopharmaceutical company serving the entire pharmaceutical value chain. We meet the world's medical needs by providing more effective and accessible treatments and innovative medicines. Since 2017, an advanced R&D system has been established covering target discovery, early detection, drug potential, preclinical, clinical research, and manufacturing transformation. Mabwell has 14 pipeline products at various stages, including his 10 new drug candidates and 4 biosimilars, based on a world-class, cutting-edge R&D engine . The company focuses on therapeutic areas such as oncology, autoimmune diseases, metabolic diseases, ophthalmology and infectious diseases. Two of these products have been approved and commercialized, two have submitted for MA approval, and three are important therapeutic agents. ordeal. Additionally, we implemented one “national major science and technology special project.”Important new drug development”, participating in two projects of the national key research and development program, and several provincial and local government science and technology innovation projects. Mabwell's Taizhou factory has strong in-house manufacturing capabilities that comply with international GMP standards regulated by NMPA, FDA, and EMA and has passed the EU. Large scale manufacturing facility located in QP Audit. Shanghai is under construction. Our mission is to “explore life, health benefits“, and our vision is “Innovation, from ideas to reality.” For more information, please visit

Forward-looking statements

This press release contains information regarding the potential safety, efficacy, regulatory review or approval, commercial success of our product candidates, and our product development, clinical studies, clinical and regulatory milestones and timelines. Contains, but is not limited to, related forward-looking statements. , market opportunities, competitive position, potential or assumed future results of operations, business strategies, potential growth opportunities, and other statements that are predictive in nature. “Forward-looking statements” are statements that are not historical facts and involve a number of risks and uncertainties that could cause actual results to differ materially from any future results expressed or implied by the forward-looking statements. There is a possibility. These statements include “anticipate,” “anticipate,” “intend,” “plan,” “believe,” “estimate,” “may,” “forecast,” and “project.” ”, “should”, “would”, and similar expressions and negative expressions of these terms.

Forward-looking statements are based on our current expectations and assumptions. Forward-looking statements are subject to numerous risks, uncertainties and other factors, many of which are beyond our control. political; economic; social; legal; dependence on our product candidates; Most are still in preclinical or various stages of clinical development. dependence on third-party vendors, such as contract research and manufacturing organizations; Uncertainty inherent in clinical testing. our ability to complete the required clinical trials for our product candidates and obtain regulatory approval for our product candidates; our ability to protect our intellectual property; the potential impact of the novel coronavirus disease (COVID-19); loss of executive officers or key employees; If one or more of these risks or uncertainties worsen, or if assumptions prove incorrect, actual results may differ materially from those stated.

The Company cautions all parties not to place undue reliance on forward-looking statements, which speak only as of the date of this press release. We may publicly update or revise any such statements to reflect changes in expectations, events, conditions or circumstances underlying such statements, except as specifically required by law and the regulations of applicable securities authorities. We are not obligated to do so. or could affect the likelihood that actual results will differ from those described in the forward-looking statements. All forward-looking statements, numbers and assumptions in this press release apply to this statement.

Sision View original content to download multimedia: at-the-14th-world-adc-london-302095573.html

Source Mabwell

Source link